Data / Research funding / Zika Virus
Zika Virus: 74 NIH awards ($134.4M) to 48 organizations
74 NIH awards ($134.4M) in the NIH spending category Zika Virus, to 48 organizations, read 2026-11-04. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
74 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| West African Center for Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,658,566 | June 9, 2020 | June 5, 2025 | WEAVER, SCOTT C | reporter.nih.gov |
| Quanitifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,011,286 | April 1, 2020 | March 31, 2026 | VAZQUEZ PROKOPEC, GONZALO MARTIN | reporter.nih.gov |
| Living in the post-Zika world: Impact of interactions between dengue and Zika viruses on diagnostics, antibody dynamics, and correlates of disease risk | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,905,886 | July 13, 2021 | April 30, 2027 | HARRIS, EVA | reporter.nih.gov |
| Validating the Flavivirus Envelope Protein as an Antiviral Target | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,735,490 | March 1, 2020 | February 28, 2026 | YANG, PRISCILLA LI-NING | reporter.nih.gov |
| Structure-based design of broad flavivirus immunogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,710,975 | September 24, 2021 | August 31, 2026 | LAI, JONATHAN R. | reporter.nih.gov |
| Research Program Award (R35 Clinical Trial Optional) - Dr. Robyn Klein NINDS | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $3,695,974 | May 1, 2021 | October 31, 2024 | CAIN, MATTHEW D | reporter.nih.gov |
| Neurodevelopment after postnatal Zika virus infection in infant macaques | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,679,627 | January 1, 2021 | November 30, 2026 | CHAHROUDI, ANN M | reporter.nih.gov |
| Evaluation of Antibody Responses Elicited by Zika Vaccination in Flavivirus-naïve and -experienced Individuals | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,665,742 | April 13, 2021 | March 31, 2027 | KREBS, SHELLY J | reporter.nih.gov |
| Development of a Replicon RNA-based Vaccine against Dengue and Zika | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,590,945 | June 1, 2021 | May 31, 2026 | SHRESTA, SUJAN | reporter.nih.gov |
| Sample-to-Answer, Rapid, Multiplexed and PCR-Free Diagnostics of Arboviral Diseases in Resource Limited Settings | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,579,220 | December 23, 2020 | November 30, 2026 | YANIK, AHMET ALI | reporter.nih.gov |
| Maternal Antibody-Mediated Enhancement of Dengue Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,138,902 | March 5, 2021 | February 28, 2026 | SHRESTA, SUJAN | reporter.nih.gov |
| Early neural predictors and neuropathogenesis of sensorimotor neurodevelopmental deficits in macaque infants exposed to Zika virus in utero | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,025,789 | June 1, 2020 | May 31, 2026 | MOHR, EMMA L | reporter.nih.gov |
| Understanding the mechanisms of antibody-mediated transcytosis of ZIKV within the placenta | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,021,123 | June 11, 2020 | May 31, 2026 | SUTHAR, MEHUL SHAMAL | reporter.nih.gov |
| Deciphering the Role of Chemokine Receptor CCR5 in Maternal Flavivirus Infections | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,021,038 | September 2, 2025 | August 31, 2029 | LIM, JEAN KYOU | reporter.nih.gov |
| A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1 | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,948,061 | January 21, 2019 | July 31, 2025 | FIKRIG, EROL | reporter.nih.gov |
| Anchimerically Activatable Anti-Zika/Dengue ProTides | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,946,770 | August 1, 2021 | July 31, 2026 | WAGNER, CARSTON R. | reporter.nih.gov |
| Childhood Outcome After In Utero ZIKV Exposure | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $2,915,429 | September 10, 2020 | June 30, 2025 | MULKEY, SARAH BETH | reporter.nih.gov |
| Dengue-Zika: Correlates of Cross-Protection in Non-Human Primates | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,724,960 | January 9, 2020 | December 31, 2025 | SARIOL, CARLOS A | reporter.nih.gov |
| Assessing desiccation tolerance's impact on Aedes aegypti midgut infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,536,503 | September 8, 2025 | August 31, 2029 | DICKSON, LAURA B | reporter.nih.gov |
| Zika virus nonstructural protein 5 inhibition of interferon signaling | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,477,738 | August 21, 2023 | July 31, 2027 | EVANS, MATTHEW J | reporter.nih.gov |
| Flavivirus immunity in endemic and non-endemic human cohorts | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,322,225 | February 16, 2021 | January 31, 2027 | MESSER, WILLIAM | reporter.nih.gov |
| Anti-flavivirus B cell response analysis to aid vaccine design | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,304,231 | February 6, 2023 | January 31, 2028 | LI, YUXING | reporter.nih.gov |
| Development of Inhibitors Targeting Flavivirus Methyltransferase | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,302,146 | April 7, 2023 | March 31, 2028 | LI, HONGMIN | reporter.nih.gov |
| ANTIBODY-BASED PROTECTION AGAINST FLAVIVIRUSES | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,212,878 | September 15, 2007 | January 31, 2029 | DIAMOND, MICHAEL S | reporter.nih.gov |
| Probing Functional States and Inhibition of Flaviviral Proteases Using Nanopore Tweezers | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,190,088 | June 10, 2021 | May 31, 2027 | CHEN, MIN | reporter.nih.gov |
| The paradox of flavivirus antigenic non-reciprocity | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,146,248 | July 24, 2024 | May 31, 2029 | FRIEDRICH, THOMAS C. | reporter.nih.gov |
| Investigating astrocytic RIPK3 as a driver of protective neuroinflammation during viral encephalitis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,142,099 | February 15, 2021 | January 31, 2027 | DANIELS, BRIAN | reporter.nih.gov |
| Interplay between AMPK and Hippo Signaling Regulates Ocular Antiviral Response to Zika virus infection | NIH | National Eye Institute | 2021 to 2024 | $2,079,783 | January 1, 2021 | December 31, 2025 | ARUMUGASWAMI, VAITHILINGARAJA | reporter.nih.gov |
| Role of microglia in neural infection | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,997,135 | January 15, 2022 | December 31, 2026 | WU, PING | reporter.nih.gov |
| Role of Zika virus (ZIKV) infection in glaucoma pathobiology | NIH | National Eye Institute | 2021 to 2025 | $1,980,186 | September 1, 2021 | August 31, 2027 | SINGH, PAWAN KUMAR | reporter.nih.gov |
| Mechanistic Insights into flavivirus NS5-mediated STAT2 Suppression | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,932,088 | March 15, 2021 | February 28, 2026 | HAI, RONG | reporter.nih.gov |
| Real-time tracking of virus evolution for vaccine strain selection and epidemiological investigation | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,886,759 | August 23, 2016 | May 31, 2026 | BEDFORD, TREVOR BC | reporter.nih.gov |
| Statistical innovation to integrate sequences and phenotypes for scalable phylodynamic inference | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,862,316 | April 9, 2021 | March 31, 2026 | SUCHARD, MARC A. | reporter.nih.gov |
| A novel strategy for vaccine-induced protection against maternal-to-fetal transmission of Zika virus | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,768,228 | June 7, 2024 | April 30, 2029 | SHRESTA, SUJAN | reporter.nih.gov |
| Impact of Zika Virus Infection on Fetal Innate and Adaptive Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,692,705 | July 12, 2024 | May 31, 2029 | ADAMS WALDORF, KRISTINA M. | reporter.nih.gov |
| Enhanced susceptibility to Zika virus during pregnancy: a role for maternal dengue antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,687,512 | September 17, 2020 | August 31, 2025 | LIM, JEAN KYOU | reporter.nih.gov |
| Multiplex serological assays to support arbovirus diagnosis, surveillance and vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,654,516 | May 11, 2020 | April 30, 2025 | DESILVA, ARAVINDA M. | reporter.nih.gov |
| A Novel Strategy for Generating Safe and Effective Flavivirus Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,606,114 | June 1, 2020 | May 31, 2026 | AUGUSTE, ALBERT J. | reporter.nih.gov |
| Treating flaviviruses with mRNA-encoded Cas13 | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,562,785 | June 13, 2024 | May 31, 2029 | SANTANGELO, PHILIP J | reporter.nih.gov |
| Meningeal Immunity and Viral Neuropathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,538,230 | August 16, 2024 | July 31, 2029 | DIAMOND, MICHAEL S | reporter.nih.gov |
| Mechanisms of tunneling nanotube formation by ZIKV NS1 in viral host interactions at the maternal-fetal interface | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,537,613 | December 1, 2023 | October 31, 2028 | JOSE, JOYCE | reporter.nih.gov |
| Molecular mechanisms linking viral replication and neuropathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,506,928 | February 8, 2023 | January 31, 2028 | SHAH, PRIYA SHIRISH | reporter.nih.gov |
| Multiplexed Detection of Mosquito-Borne Viruses at the Point-of-Care | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,482,375 | February 11, 2021 | January 31, 2026 | FAN, Z. HUGH | reporter.nih.gov |
| How flaviviruses hijack a host transmembrane protein chaperone to promote viral infection | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,424,560 | September 20, 2021 | July 31, 2025 | TAI, ANDREW W. | reporter.nih.gov |
| Understanding mosquito movement and its relevance to control through genetic analysis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,392,640 | September 21, 2020 | August 31, 2025 | MARSHALL, JOHN MACKY | reporter.nih.gov |
| Long-term language outcomes in children with prenatal virus exposure | NIH | National Institute on Deafness and Other Communication Disorders | 2024 to 2025 | $1,253,694 | April 1, 2024 | March 31, 2029 | HOOD, LINDA J. | reporter.nih.gov |
| Clinical progression and predictors of outcomes in congenital Zika syndrome | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $1,248,888 | August 1, 2024 | April 30, 2029 | WHEELER, ANNE CAROLINE | reporter.nih.gov |
| Gigapixel Next-Generation-Sequencing: An Ultra-Sensitive Diagnostic for Infections of the CNS | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,221,032 | November 1, 2023 | October 31, 2027 | ABATE, ADAM R. | reporter.nih.gov |
| Implications of sequential bloodmeals on arbovirus transmission by mosquitoes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,188,325 | May 12, 2020 | April 30, 2026 | BRACKNEY, DOUGLAS E. | reporter.nih.gov |
| Development of a vaccination platform for emerging flavivirus infections | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $919,536 | November 4, 2021 | October 31, 2026 | BECKHAM, JOHN DAVID | reporter.nih.gov |
| Novel Aglains as Therapeutic Agents for Mosquito-borne Arboviruses | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $808,919 | September 18, 2025 | August 31, 2030 | PORCO, JOHN A. | reporter.nih.gov |
| Molecular mechanism of Zika virus-induced premature craniofacial suture closure | NIH | National Institute of Dental & Craniofacial Research | 2024 to 2025 | $805,000 | January 1, 2024 | December 31, 2028 | CHEN, WEIQIANG | reporter.nih.gov |
| A Novel T cell-based Vaccine to Prevent Dengue/Zika virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $781,718 | June 1, 2025 | March 31, 2026 | QIAO, LIANG | reporter.nih.gov |
| Defining Molecular Epitopes of Protective Antibodies to Flaviviruses | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $780,940 | February 4, 2022 | January 31, 2027 | MARKMANN, ALENA JANDA | reporter.nih.gov |
| Innate Immunity of Zika Virus Infection In Human Neural Progenitors | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $777,770 | April 16, 2020 | March 31, 2026 | STOKES, CALEB | reporter.nih.gov |
| Defining the molecular interactions required for flavivirus genome packaging and virus assembly | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $771,179 | August 10, 2023 | July 31, 2025 | JOSE, JOYCE | reporter.nih.gov |
| Molecular regulatory mechanism of Zika virus-induced intracranial calcifications | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2024 | $746,997 | May 1, 2022 | April 30, 2025 | CHEN, WEIQIANG | reporter.nih.gov |
| Arbovirus Transmission Dynamics Across a Metapopulation Undergoing Environmental and Social Change | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $699,339 | November 19, 2024 | October 31, 2029 | EISENBERG, JOSEPH N. S. | reporter.nih.gov |
| Host Regulation of Flavivirus Infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $530,385 | June 6, 2025 | May 31, 2030 | GACK, MICHAELA ULRIKE | reporter.nih.gov |
| Discovery and Development of Oral Small-molecule Direct-acting Antivirals | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $499,825 | September 29, 2025 | September 29, 2026 | SCARNEO, SCOTT | reporter.nih.gov |
| Development of MS2045 for inhibition of Zika methyltransferase | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $464,750 | January 2, 2023 | December 31, 2024 | AGGARWAL, ANEEL K. | reporter.nih.gov |
| The mechanism of flaviviral suppression of vitamin A metabolism | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $457,250 | July 19, 2023 | June 30, 2025 | WANG, PENGHUA | reporter.nih.gov |
| Human cutaneous responses to arthropod-mediated viral transmission | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $449,625 | July 8, 2025 | July 7, 2027 | DOUAM, FLORIAN | reporter.nih.gov |
| Big Data Predictive Phylogenetics with Bayesian Learning | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $425,868 | June 1, 2020 | May 31, 2025 | HOLBROOK, ANDREW JAMES | reporter.nih.gov |
| Functional Role of Pseudouridine on Zika Virus Gene Expression | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $422,797 | June 9, 2023 | May 31, 2025 | PAGER, CARA THERESIA | reporter.nih.gov |
| Determinants of acute and persistent Zika virus shedding in semen | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $421,088 | June 1, 2024 | April 30, 2027 | DUGGAL, NISHA | reporter.nih.gov |
| Human Genetic Variation Regulating Cellular Susceptibility to Zika Virus | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $420,757 | June 1, 2024 | April 30, 2026 | KO, DENNIS CHUN-YONE | reporter.nih.gov |
| Developing a Chiropteran model to study the impact of thermal stress on antiviral immunity and inflammatory responses | NIH | Office of the Director, National Institutes of Health | 2024 to 2025 | $250,005 | July 1, 2024 | June 30, 2029 | FAGRE, ANNA | reporter.nih.gov |
| MECHANISMS REGULATING BREACH OF BLOOD RETINAL BARRIER UPON ZIKA VIRUS INFECTION | NIH | National Eye Institute | 2024 to 2025 | $242,180 | September 30, 2024 | August 31, 2026 | SINGH, SNEHA | reporter.nih.gov |
| Role of Mertk in pathological neurodevelopment in mice with congenital Zika virus infection | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $234,359 | January 15, 2025 | December 31, 2029 | AGNER, SHANNON CHRISTINE | reporter.nih.gov |
| Unveiling Mechanisms of ZIKV-Induced Cardiac Dysfunction in a mouse model | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $154,500 | August 13, 2025 | July 31, 2029 | TANG, QIYI | reporter.nih.gov |
| Characterizing host proteins that restrict Zika virus | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $83,421 | August 1, 2024 | January 31, 2026 | WILLCOX, ALEXANDRA CLAIBORNE | reporter.nih.gov |
| Novel Antiviral Agents Targeting Zika and Dengue Virus | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $80,000 | August 1, 2025 | July 31, 2027 | LI, XIN | reporter.nih.gov |
| Defining Long Term Neurological Consequences Following Asymptomatic ZIKV Infection | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $39,298 | September 1, 2025 | August 31, 2028 | DAPRANO, EVAN | reporter.nih.gov |
Organizations
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 49 | $31,084,364 | 0 | $0 |
| 2024 | 62 | $34,813,331 | 0 | $0 |
| 2023 | 44 | $25,326,372 | 0 | $0 |
| 2022 | 37 | $22,554,696 | 0 | $0 |
| 2021 | 33 | $20,603,094 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 56 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 56 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 56 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 56 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 56 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 56 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 56 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 56 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 56 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 56 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 56 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 56 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 56 awards here |
| Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) | RFA-AI-28-024 | NIH | 93.855 | February 11, 2027 | Not listed | Same assistance listing 93.855 as 56 awards here |
| NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) | RFA-LM-28-001 | NIH | 93.855 | February 11, 2027 | $775,000 | Same assistance listing 93.855 as 56 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 56 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 56 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 56 awards here |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 56 awards here |
| Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required) | PA-24-187 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 56 awards here |
Updated November 4, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-04). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.